Durata Therapeutics To Present Two Dalbavancin Posters At The 23rd Annual ECCMID Meeting

CHICAGO, April 24, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced that data from two clinical trials of the company's lead product candidate, dalbavancin, will be presented in two posters at the 23 rd Annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), which takes place in Berlin, Germany from April 27-30, 2013.

The following posters will be presented:
Saturday, April 27, 2013
15:30 - 16:30
Title: A study to evaluate the safety, tolerability, and pharmacokinetics of multiple weekly doses of intravenous dalbavancin in healthy subjects
Authors: M. Dunne, C. Sprenger, S. Moriarty (Branford, US)
Poster #: P910
 
Sunday, April 28, 2013 
13:30 - 14:30
Title: Dalbavancin activity in the USA: reported from the SENTRY Programme (2012)
Authors: R.N. Jones, R.K. Flamm, H.S. Sader, B.P. Goldstein, M. Dunne (North Liberty, Morristown, US)
Poster #: P1646

Copies of these posters will be available on Durata's website following the ECCMID Meeting:  www.duratatherapeutics.com.  

About Dalbavancin

Dalbavancin is an intravenous antibiotic product candidate under investigation for once-weekly dosing, which we believe may facilitate the treatment of patients with ABSSSI in both the in-patient and out-patient settings, potentially reducing the length of a patient's hospital stay or avoiding hospital admission altogether, with an impact on the overall cost of care for these patients. 

About Durata Therapeutics

Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Durata has completed two global Phase 3 clinical trials with its lead product candidate, dalbavancin, under investigation for the treatment of patients with acute bacterial skin and skin structure infections, or ABSSSI.

Forward-looking Statements

Statements contained in this press release contain forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
CONTACT: Investor Relations and Public Affairs Contact         Allison Wey         Durata Therapeutics         Vice President, Investor Relations and Public Affairs         (312) 219-7017         awey@duratatherapeutics.com                  Media Relations Contact         Jed Weiner         White Oak Communications, Inc.         (847) 392-4186         jed.weiner@comcast.net

Durata Therapeutics, Inc. Logo

More from Press Releases

NFL Pushes for Regulation Following Supreme Court's Sports Gambling Ruling

NFL Pushes for Regulation Following Supreme Court's Sports Gambling Ruling

21st Century Fox Scoops Up Local News Stations

21st Century Fox Scoops Up Local News Stations

Walmart CEO: 'We Are Transforming Globally' With Flipkart

Walmart CEO: 'We Are Transforming Globally' With Flipkart

Three-Part FREE Webinar Series

Three-Part FREE Webinar Series

March 24 Full-Day Course Offering: Professional Approach to Trading SPX

March 24 Full-Day Course Offering: Professional Approach to Trading SPX